{
  "signal_id": "SIG-2026-007",
  "observed_date": "2026-02-24",
  "category": "Healthspan Therapeutics + Trial Design",
  "title": "PROSPR VITAL-H will test repurposed drugs in a phase 3 hybrid aging trial",
  "what_changed": "The VITAL-H team plans a phase 3 hybrid trial evaluating repurposed FDA-approved drugs including an SGLT2 inhibitor, rapamycin, and semaglutide in an effort to establish a regulatory path for therapeutics targeting aging outcomes.",
  "why_it_matters": "The program may create one of the clearest U.S. precedents for linking existing therapeutics, healthspan endpoints, and a regulatory pathway.",
  "affected_actors": [
    "ARPA-H",
    "UT Health San Antonio",
    "FDA",
    "trial sites",
    "biopharma",
    "patients"
  ],
  "decision_implication": "Track protocol, endpoints, regulatory interactions, safety management, and whether results support an aging/healthspan indication pathway.",
  "status": "Active R&D",
  "evidence_class": "E5 — official federal award description",
  "impact": 5,
  "immediacy": 3,
  "relevance": 5,
  "novelty": 5,
  "adoption_leverage": 5,
  "priority_score": 92,
  "sources": [
    "https://arpa-h.gov/explore-funding/awards/4176"
  ],
  "public_slug": "/signal/2026-02-24-vital-h-phase-3/",
  "watch_conditions": [
    "Trial initiation",
    "endpoint selection",
    "FDA engagement",
    "outcome data."
  ],
  "last_verified": "2026-08-08",
  "version": "1.0"
}